MAINZ BIOMED N.V.
Datakwaliteit: 100%
QUCY
Nasdaq
Manufacturing
Chemicals
€ 0,48
▼
€ 0,04
(-7,71%)
Marktkapitalisatie: 6,00 M
Prijs
€ 0,48
Marktkapitalisatie
6,00 M
Dagbereik
€ 0,46 — € 0,52
52-Weeksbereik
€ 0,40 — € 4,43
Volume
545.616
Openen € 0,50
50D / 200D Gem.
€ 0,77
37,65% below
50D / 200D Gem.
€ 1,29
62,94% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -10,98 M
Capital efficient — spends only 0,23% of revenue on capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-2526,61%
Onder sectorgemiddelde (-51,02%)
ROIC-492,09%
Net Margin-3018,31%
Op. Margin-3004,97%
Veiligheid
Debt / Equity
1,49
Boven sectorgemiddelde (0,33)
Current Ratio0,50
Interest Coverage-43,22
Waardering
PE (TTM)
-0,37
Boven sectorgemiddelde (-1,98)
P/B Ratio9,35
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,4 | -2,0 |
| P/B | 9,4 | 5,1 |
| ROE % | -2526,6 | -51,0 |
| Net Margin % | -3018,3 | -150,2 |
| Rev Growth 5Y % | — | 9,3 |
| D/E | 1,5 | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 537.080,0 | Net Income (TTM) | -16,21 M |
| ROE | -2526,61% | ROA | -304,29% |
| Gross Margin | 72,58% | Operating Margin | -3004,97% |
| Net Margin | -3018,31% | Free Cash Flow (TTM) | -10,98 M |
| ROIC | -492,09% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1,49 | Current Ratio | 0,50 |
| Interest Coverage | -43,22 | Asset Turnover | 0,10 |
| Working Capital | -1,85 M | Tangible Book Value | -471.824 |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,37 | Forward P/E | N/A |
| P/B Ratio | 9,35 | P/S Ratio | 11,17 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -183,06% | ||
| Market Cap | 6,00 M | Enterprise Value | 6,96 M |
| Per Share | |||
| EPS (Diluted TTM) | -2,70 | Revenue / Share | 0,04 |
| FCF / Share | -0,88 | OCF / Share | -0,88 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,23% | FCF Conversion | 67,74% |
| SBC-Adj. FCF | -12,45 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 |
|---|---|
| Revenue | 537.080,0 |
| Net Income | -16,21 M |
| EPS (Diluted) | -2,70 |
| Gross Profit | 389.792,0 |
| Operating Income | -16,14 M |
| EBITDA | — |
| R&D Expenses | 4,91 M |
| SG&A Expenses | — |
| D&A | 615.720,0 |
| Interest Expense | 373.458,0 |
| Income Tax | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 |
|---|---|
| Total Assets | 5,33 M |
| Total Liabilities | 4,69 M |
| Shareholders' Equity | 641.600,0 |
| Total Debt | 956.902,0 |
| Cash & Equivalents | — |
| Current Assets | 1,84 M |
| Current Liabilities | 3,69 M |
{"event":"ticker_viewed","properties":{"ticker":"QUCY","listing_kind":"stock","pathname":"/stocks/qucy","exchange":"Nasdaq","country":"US"}}